Respiratory syncytial virus (RSV) has emerged as a leading cause of pneumonia, with high mortality, in bone marrow transplant (BMT) recipients, as well as in other profoundly immunocompromised patients, such as myelosuppressed adults with leukemia. We tested the efficacy of immunoglobulin with high anti-RSV neutralizing antibody levels (RSVIG) for prophylaxis and therapy of RSV infection in cotton rats undergoing prolonged immunosuppression with cyclophosphamide. These animals experience persistent infection, a model which is similar to the disease seen in post-BMT humans. Both prophylaxis and therapy reduced pulmonary viral replication over 500-fold to nearly undetectable levels. In animals receiving continual immunosuppression, the use of multiple therapeutic doses of RSVIG was able to prevent rebound viral replication, though virus was not completely eliminated. Keywords: RSV; BMT; immunotherapy; RSVIG; cyclophosphamide; cotton rat Advances in bone marrow transplantation (BMT) have led to a large increase in the number of procedures done, partially due to increasingly aggressive attempts to cure patients of several types of malignancy as well as a variety of other systemic diseases. However, gains due to improvements in BMT are still offset by high rates of morbidity and mortality due to infectious diseases in the immediate post-transplant period. A variety of methods have been effective in reducing rates of some early opportunistic infections, such as cytomegalovirus and Pneumocystis carinii.
Advances in bone marrow transplantation (BMT) have led to a large increase in the number of procedures done, partially due to increasingly aggressive attempts to cure patients of several types of malignancy as well as a variety of other systemic diseases. However, gains due to improvements in BMT are still offset by high rates of morbidity and mortality due to infectious diseases in the immediate post-transplant period. A variety of methods have been effective in reducing rates of some early opportunistic infections, such as cytomegalovirus and Pneumocystis carinii. 1 In contrast, respiratory syncytial virus (RSV), a ubiquitous respiratory virus considered by many to be a significant pathogen only during infancy, has emerged as a major cause of morbidity and mortality in BMT recipients of all ages. 2 Attempts to treat this infection with the antiviral agent ribavirin have been largely unsuccessful, and BMT patients who develop RSV pneumonia have extremely high rates of mortality.
in preventing severe RSV disease in high risk infants, 7, 8 and may have some therapeutic potential. 9, 10 To evaluate the potential use of RSVIG in BMT recipients, we turned to the model of RSV infection in immunosuppressed cotton rats.
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Materials and methods
Animals
Weanling inbred cotton rats (Sigmodon hispidus) were obtained from Virion Systems Inc. Animals were housed in large polycarbonate cages in small groups, and were provided water and rat chow ad libitum.
Immunosuppression
Animals were treated with intraperitoneal (i.p.) injections of cyclophosphamide (CY) at a dose of 50 mg/kg three times weekly for at least 21 days prior to viral challenge. Immunosuppressive therapy was continued until the end of each experiment. To monitor the level of immunosuppression during these experiments, selected suppressed and control animals were bled for complete blood count (CBC) and white blood cell differential counts at the time of viral challenge. Nasal and pulmonary virus titers were determined at several intervals post viral challenge.
Virus
The long strain of RSV (Group A), obtained from the American Type Culture Collection, was used as the challenge virus. A single pool propagated in HEp-2 cells containing 1 × 10 6 plaque forming units (p.f.u.) per ml was used for all experiments.
Virus assay
Animals were sacrificed by carbon dioxide asphyxiation. Lung and nasal tissues (including turbinates) were homogenized in 10 parts (weight/vol) of Hanks' balanced salt solution supplemented with 0.218 m sucrose, 4.4 mm glutamate, 3.8 mm KH 2 HPO 4 and 7.2 mm K 2 HPO 4 (to stabilize virus during freeze-thawing); and supernatants were stored at Ϫ70 o C until assayed. Viral titers were determined by plaque assay as described, 12 and were calculated as plaque forming units per gram tissue. 
Immunoglobulin preparations
A 5% solution of RSVIG (provided by MedImmune, Inc, Gaithersburg, MD, USA) was used for all experiments. It possessed a reciprocal neutralizing antibody titer of 6000 for a 1% solution.
Experimental designs
To assess the effectiveness of immunoprophylaxis, CYsuppressed and control animals received intraperitoneal doses of RSVIG 24 h prior to intranasal inoculation with 0.1 ml (10 5 p.f.u.) of RSV under light anesthesia with methoxyfluorane, and were sacrificed via CO 2 asphyxiation for tissue virus titration 4 days later. The effectiveness of immunotherapy was assessed by administering intraperitoneal doses of RSVIG to CY-suppressed and control animals 3 days after infection, which were sacrificed for tissue virus tiration 1 day thereafter. The possibility of rebound of replication in CY-suppressed and normal control animals who received single dose RSVIG prophylaxis or therapy, was investigated by measuring tissue virus titers on days 4, 8, 12, and 16 after RSV infection. In a related experiment, single vs multiple doses of immunotherapy were compared in CY-suppressed and normal control animals over an identical 16-day period.
Statistical analysis
All viral and serologic titrations were calculated as geometric means Ϯ standard error within group. Viral titers were compared for significance by Student's t-test.
Results
Effectiveness of immunosuppression
Leukopenia was noted at day 21 in uninfected animals receiving CY. Mean total WBC were 11.55 ϫ 10 9 /l in control animals vs 3.37 ϫ 10 9 /l in CY-treated animals. In particular, absolute neutrophil and lymphocyte counts each fell by more than 80%. Pulmonary and nasal RSV titers were slightly higher on day 4 in suppressed vs control animals (ie infected but immunocompetent) as shown in Figure 1a and b. Pulmonary and nasal titers were nearly 10-fold higher between suppressed and control animals on day 6 of infection (not shown). These high virus titers (10 6 p.f.u./g tissue in lungs and noses) persisted unchanged for at least 16 days in continually suppressed animals, while control animals were virus-free by day 8. 
Effectiveness of immunoprophylaxis
Three groups each of CY-suppressed and control animals (six animals per group), received prophylactic doses of RSVIG (either 2, 0.5, or 0.125 g/kg). Twenty-four hours later these animals, together with an additional group each of suppressed and control animals not receiving RSVIG, were intranasally infected with 10 5 p.f.u. of RSV. On the fourth day after infection they were sacrificed. Figure 1a summarizes these experiments. Pulmonary and nasal viral titers in all groups receiving 2.0 or 0.5 mg/kg of RSVIG were significantly reduced when compared to control groups (P Ͻ 0.001). The 0.125 g/kg dose also reduced pulmonary replication (P Ͻ 0.001), but less so in the nose (P Ͻ 0.05). RSVIG prophylaxis equally reduced RSV replication in CY-suppressed and control animals.
Effectiveness of immunotherapy
Three groups of six CY-suppressed and control animals received therapeutic doses of RSVIG (either 2, 0.5 or 0.125 g/kg), 3 days after infection, and were sacrificed 1 day thereafter. Pulmonary and nasal titers in all groups receiving RSVIG were significantly reduced when compared to control groups (Figure 1b , P Ͻ 0.001). As with RSVIG prophylaxis, therapy was equally effective in CY-suppressed and control animals.
Rebound of viral replication
Since viral replication continues at a high level in pulmonary and nasal tissues for more than 2 weeks in CYsuppressed animals, the possibility of rebound of replication after RSVIG treatment was addressed. Three groups each (eight animals per group) of CY-suppressed or normal control animals were RSV-infected and received one of the following regimens: 0.5 g/kg of RSVIG 24 h prior to infection; the same dose 72 h after infection; or no RSVIG. Two animals from each group were sacrificed each on days 4, 8, 12, and 16. These experiments were repeated twice, with total numbers, representing six animals per time point, displayed in Figure 2a . By day 8 after viral challenge, nonsuppressed non-treated animals completely cleared RSV without rebound, while CY-suppressed animals not receiving RSVIG had 10 5-6 p.f.u./g of RSV recovered from pulmonary tissues through the 16-day period. In non-suppressed animals which received prophylactic RSVIG, a small amount of pulmonary viral replication was noted on day 4, while those which received RSVIG treatment had no recoverable virus on day 4. No RSV was recovered from the lungs of either group at any time after day 4. In contrast, CY-suppressed animals which received RSVIG prophylaxis or therapy demonstrated similar reductions in pulmonary virus titers on day 4, as described above, but demonstrated rebound of viral replication on days 8 and 12 with pulmon-ary viral titers diminishing thereafter. In all groups, nasal viral titers paralleled those in lungs.
Multiple RSVIG infusions to blunt rebound
The effectiveness of multiple therapeutic doses of RSVIG was evaluated. Non-suppressed animals, which received either no RSVIG or one dose (0.5 mg/kg) on day 3 of infection, were compared to CY-suppressed animals receiving one dose (0.5 g/kg) on day 3, or four doses (0.5 g/kg) on days 3, 7, 11, and 15. Animals from each group were sacrificed on days 4, 8, 12, and 16. This experiment was run twice, with a total of at least six animals sampled per time point. In the CY-suppressed animals which received one therapeutic dose of RSVIG (Figure 2b ), viral replication rebounded to nearly 10 4 p.f.u./g pulmonary tissue, then dropped after day 12. In contrast, animals which received sequential doses of RSVIG therapy displayed a modest amount of viral replication on day 4, with pulmonary viral titers rapidly dropping to less than 10 2.5 p.f.u./g in pulmonary tissues. Again, nasal viral titers paralleled pulmonary tissue titers.
Discussion
A primary cause of morbidity and mortality in severely immunosuppressed patients, such as those who have recently received a bone marrow transplant or intense myelosuppressive chemotherapy without transplantation, is infectious pneumonia. In 1985 one of the first cases of fatal pneumonia due to RSV in a BMT recipient was reported. 13 This was rapidly followed by several reports of RSV outbreaks in BMT recipients of all ages. [3] [4] [5] [6] A recent symposium reported that RSV is now the leading cause of fatal pneumonia in the immediate post-transplant period, 2 dramatically impacting on transplant units during seasonal community outbreaks, with case fatality rates of greater than 50% in BMT recipients of all ages, and near universal lethality in patients requiring mechanical ventilatory support. [3] [4] [5] [6] Early reports noted only minimal increased survival in BMT patients with severe RSV pneumonia treated with ribavirin. 6, 14 Increased success appears to be occurring with combined ribavirin and IVIG therapy. In one study, there was improved survival (7/9 survivors) if therapy was initiated early and prior to the need for mechanical ventilation. 15 Mortality was still 100% in three patients whose therapy was begun after mechanical ventilation. A recent report described two adult patients, who responded well to a combination of ribavirin and RSVIG. 16 The same author recently presented a series of pediatric BMT recipients who received combination ribavirin and RSVIG therapy for RSV pneumonia, which resulted in survival in 10 of 11 patients, a marked improvement compared with historical survival rates in similar patients. 17 In the cotton rat model, using cytotoxic immunosuppression comparable to that used in BMT regimens, we were able to establish a prolonged high-titer pulmonary RSV infection, which may in some ways parallel the disease seen in BMT recipients. Both prophylactic and therapeutic RSVIG, even in modest doses, were effective in reducing or eliminating viral replication in suppressed animals. Although rebound of pulmonary viral replication was observed in animals receiving continued immunosuppression, levels of viral replication were more effectively reduced by repeated doses of RSVIG. As past experience with this animal model 18 predicted the success of prophylactic use of RSVIG in high risk infants, 7, 8 these studies suggest a role for RSVIG immunoprophylaxis and therapy in BMT patients.
